We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
- Authors
Patnaik, Amita; LoRusso, Patricia M; Messersmith, Wells A; Papadopoulos, Kyriakos P; Gore, Lia; Beeram, Muralidhar; Ramakrishnan, Vanitha; Kim, Amy H; Beyer, Joseph C; Mason Shih, L; Darbonne, Walter C; Xin, Yan; Yu, Ron; Xiang, Hong; Brachmann, Rainer K; Weekes, Colin D
- Abstract
MNRP1685A is a human monoclonal antibody that blocks binding of vascular endothelial growth factor (VEGF), VEGF-B, and placental growth factor 2 to neuropilin-1 resulting in vessel immaturity and VEGF dependency. The safety of combining MNRP1685A with bevacizumab, with or without paclitaxel, was examined.
- Publication
Cancer chemotherapy and pharmacology, 2014, Vol 73, Issue 5, p951
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-014-2426-8